G
GRFS
Grifols S A
7.46
+0.05+0.67%After Hours: 7.46 0.00 0.00%16:10 10/09 EDT
OPEN/PREV CLOSE7.51/7.41
TODAY RANGE7.44-7.53
VOL330.56K
MARKET CAP5.13B
52 WEEK RANGE6.86-9.75
AVG VOL (3M)574.74K
% TURNOVER0.05%
TURNOVER--
P/E (TTM)9.82
% RANGE1.21%
EPS(TTM)0.7596
P/E(FORWARD)7.53
P/B0.8014
BVPS9.31
DIVIDEND0.0942
P/S0.5749
BETA--
DIV YIELD1.26%
FREE FLOAT MKT CAP5.13B
SHARES OUTSTANDING687.55M
NEXT EARNINGS11/02-11/06
FREE FLOAT687.55M
LOT SIZE1
EX-DATE07/02/2026
News
Press Releases
Financial Reports
Profile
Seeking Alpha·09/17 01:33
Grifols: Better Plasma Economics Can Unlock A Discounted Equity
NASDAQ·09/08 15:40
GRFS or SDZNY: Which Is the Better Value Stock Right Now?
Seeking Alpha·08/18 13:52
Oakmark International Small-Cap Strategy reshuffles portfolio with six new positions in Q2
Seeking Alpha·08/15 05:25
Oakmark International Small Cap Strategy Q2 2026 Portfolio Update
TipRanks·08/10 11:40
Grifols completes clinical portion of SPARTA trial
TipRanks·07/30 15:17
Grifols Reshapes Board and Committee Leadership After Director Resignation
TipRanks·07/29 17:55
Grifols says EXCELL Phase 3 trial timeline not ‘new development or a delay’
NASDAQ·07/29 01:12
Grifols (GRFS) Q2 2026 Earnings Call Transcript
TipRanks·07/29 00:19
Grifols Earnings Call Highlights Biopharma Momentum, Cash Gains
NASDAQ·07/28 17:37
Grifols H1 Profit Rises 29%; Backs FY26 Outlook
Seeking Alpha·07/27 22:00
Here are the major earnings before the open Tuesday
Seeking Alpha·07/16 19:24
Oakmark International Small Cap Fund Q2 2026 Portfolio Activity
TipRanks·07/16 12:10
Grifols doses first patients in two Gamunex-C trials